ceftriaxone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	564	73384-59-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ceftriaxone sodium hydrate ceftriaxone biotrakson rocefin rocephalin rophex ceftriaxone sodium	A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Molecular weight: 554.57 Formula: C18H18N8O7S3 CLOGP: 0.02 LIPINSKI: 2 HAC: 15 HDO: 4 TPSA: 208.98 ALOGS: -3.72 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ceftriaxone sodium hydrate
ceftriaxone
biotrakson
rocefin
rocephalin
rophex
ceftriaxone sodium

A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.

Molecular weight: 554.57
Formula: C18H18N8O7S3
CLOGP: 0.02
LIPINSKI: 2
HAC: 15
HDO: 4
TPSA: 208.98
ALOGS: -3.72
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	P
2	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	400 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	46 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	120.27 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.22 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 21, 1984	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	715.09	52.54	170	2819	5348	2349748
Toxic epidermal necrolysis	427.86	52.54	101	2888	3043	2352053
Acute kidney injury	395.70	52.54	157	2832	27965	2327131
Rash	365.94	52.54	186	2803	59372	2295724
Cholelithiasis	352.55	52.54	98	2891	5705	2349391
Acute generalised exanthematous pustulosis	309.71	52.54	69	2920	1589	2353507
Pyrexia	292.65	52.54	155	2834	53553	2301543
Hepatitis	268.86	52.54	81	2908	6256	2348840
Anaphylactic shock	262.92	52.54	73	2916	4213	2350883
Erythema	247.19	52.54	109	2880	25050	2330046
Jarisch-Herxheimer reaction	246.22	52.54	37	2952	64	2355032
Pruritus	243.93	52.54	128	2861	43212	2311884
Drug ineffective	235.72	52.54	170	2819	101454	2253642
Haemolytic anaemia	227.42	52.54	55	2934	1826	2353270
Stevens-Johnson syndrome	226.97	52.54	65	2924	4194	2350902
Urticaria	221.85	52.54	100	2889	24161	2330935
Multiple organ dysfunction syndrome	217.27	52.54	72	2917	7569	2347527
Dyspnoea	208.38	52.54	143	2846	78590	2276506
Tubulointerstitial nephritis	189.10	52.54	50	2939	2388	2352708
Pseudocholelithiasis	183.75	52.54	24	2965	0	2355096
Rash maculo-papular	170.09	52.54	52	2937	4200	2350896
Factor V inhibition	169.76	52.54	24	2965	19	2355077
Hypotension	160.14	52.54	88	2901	32348	2322748
Condition aggravated	155.77	52.54	86	2903	31893	2323203
Pneumonia	155.19	52.54	100	2889	49196	2305900
Drug hypersensitivity	152.71	52.54	97	2892	46546	2308550
Anaphylactic reaction	152.65	52.54	59	2930	9646	2345450
Postrenal failure	146.36	52.54	22	2967	38	2355058
Clostridium difficile colitis	143.98	52.54	39	2950	2040	2353056
Tachycardia	138.24	52.54	64	2925	16345	2338751
Thrombocytopenia	134.86	52.54	66	2923	19065	2336031
Eosinophilia	134.56	52.54	40	2949	2930	2352166
Agranulocytosis	132.50	52.54	41	2948	3441	2351655
Maternal exposure during pregnancy	131.54	52.54	60	2929	14803	2340293
Status epilepticus	128.22	52.54	37	2952	2441	2352655
Haemophagocytic lymphohistiocytosis	119.87	52.54	31	2958	1352	2353744
Septic shock	118.44	52.54	45	2944	7009	2348087
Drug interaction	116.56	52.54	69	2920	29094	2326002
Neutropenia	107.62	52.54	59	2930	21489	2333607
Sepsis	104.58	52.54	55	2934	18433	2336663
Angioedema	100.62	52.54	42	2947	8354	2346742
Drug resistance	100.24	52.54	31	2958	2593	2352503
Hypersensitivity	94.66	52.54	56	2933	23537	2331559
Drug-induced liver injury	93.67	52.54	32	2957	3667	2351429
Anaemia	93.29	52.54	64	2925	34728	2320368
Diarrhoea	92.94	52.54	92	2897	83472	2271624
Cardiac arrest	91.82	52.54	47	2942	14883	2340213
Pancytopenia	91.18	52.54	43	2946	11409	2343687
Hydronephrosis	88.77	52.54	24	2965	1243	2353853
Haemolysis	88.21	52.54	23	2966	1035	2354061
Respiratory failure	87.30	52.54	44	2945	13484	2341612
Leukocytosis	86.91	52.54	30	2959	3546	2351550
Vomiting	85.48	52.54	82	2907	71520	2283576
Cholecystitis	83.59	52.54	26	2963	2214	2352882
Cholangitis	82.57	52.54	21	2968	855	2354241
Hypoxia	80.85	52.54	33	2956	6194	2348902
Dermatitis bullous	80.20	52.54	23	2966	1481	2353615
Abdominal pain	79.97	52.54	58	2931	34316	2320780
Encephalopathy	76.16	52.54	29	2960	4532	2350564
Laryngeal stenosis	75.74	52.54	13	2976	68	2355028
Symmetrical drug-related intertriginous and flexural exanthema	73.37	52.54	12	2977	44	2355052
Influenza B virus test positive	72.45	52.54	11	2978	21	2355075
Choreoathetosis	71.75	52.54	14	2975	162	2354934
Blister	71.57	52.54	31	2958	6740	2348356
Cholestasis	70.66	52.54	26	2963	3695	2351401
Disseminated intravascular coagulation	69.54	52.54	25	2964	3325	2351771
Clostridium difficile infection	69.26	52.54	24	2965	2866	2352230
Lip oedema	68.53	52.54	18	2971	833	2354263
Anuria	67.33	52.54	21	2968	1803	2353293
Dermatitis exfoliative	66.26	52.54	19	2970	1222	2353874
Alanine aminotransferase increased	66.07	52.54	37	2952	13995	2341101
Enterococcal infection	65.86	52.54	17	2972	734	2354362
Exposure during pregnancy	64.24	52.54	45	2944	25174	2329922
Renal failure	63.87	52.54	39	2950	17310	2337786
Acute respiratory distress syndrome	62.49	52.54	23	2966	3269	2351827
Linear IgA disease	62.00	52.54	14	2975	340	2354756
Rash erythematous	61.97	52.54	27	2962	5949	2349147
Depressed level of consciousness	61.86	52.54	29	2960	7575	2347521
Autoimmune haemolytic anaemia	61.39	52.54	16	2973	718	2354378
Pseudomembranous colitis	60.78	52.54	15	2974	539	2354557
Unresponsive to stimuli	60.42	52.54	25	2964	4851	2350245
Klebsiella infection	59.69	52.54	16	2973	801	2354295
Aspartate aminotransferase increased	58.67	52.54	33	2956	12579	2342517
Respiratory disorder	58.11	52.54	23	2966	3981	2351115
Langerhans' cell histiocytosis	56.95	52.54	10	2979	61	2355035
Loss of consciousness	56.13	52.54	37	2952	18730	2336366
Respiratory distress	55.88	52.54	24	2965	5105	2349991
Premature delivery	55.77	52.54	21	2968	3179	2351917
Altered state of consciousness	55.41	52.54	22	2967	3838	2351258
Respiratory acidosis	54.92	52.54	15	2974	806	2354290
Shock	54.63	52.54	22	2967	3982	2351114
Hepatocellular injury	54.36	52.54	22	2967	4033	2351063
Hepatitis cholestatic	54.18	52.54	16	2973	1141	2353955

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Postrenal failure	491.60	45.73	77	2872	93	1743739
Drug reaction with eosinophilia and systemic symptoms	378.75	45.73	112	2837	4958	1738874
Acute kidney injury	373.75	45.73	186	2763	34758	1709074
Cholelithiasis	359.20	45.73	97	2852	3068	1740764
Jarisch-Herxheimer reaction	326.63	45.73	56	2893	158	1743674
Drug ineffective	276.69	45.73	189	2760	63612	1680220
Rash	274.63	45.73	157	2792	38536	1705296
Pruritus	260.27	45.73	128	2821	23094	1720738
Hydronephrosis	254.34	45.73	62	2887	1283	1742549
Pyrexia	243.17	45.73	155	2794	46245	1697587
Anaphylactic reaction	232.77	45.73	81	2868	6032	1737800
Toxic epidermal necrolysis	228.59	45.73	64	2885	2307	1741525
Ureterolithiasis	227.12	45.73	45	2904	332	1743500
Anaphylactic shock	202.83	45.73	61	2888	2838	1740994
Urticaria	191.01	45.73	85	2864	12156	1731676
Rash maculo-papular	184.06	45.73	60	2889	3643	1740189
Acute generalised exanthematous pustulosis	158.59	45.73	41	2908	1081	1742751
Erythema	157.80	45.73	78	2871	14110	1729722
Drug-induced liver injury	154.97	45.73	51	2898	3186	1740646
Anuria	150.62	45.73	44	2905	1844	1741988
Neutropenia	144.74	45.73	80	2869	18180	1725652
Dyspnoea	143.32	45.73	118	2831	51941	1691891
Hypotension	139.69	45.73	93	2856	29561	1714271
Tubulointerstitial nephritis	139.15	45.73	46	2903	2912	1740920
Haemolytic anaemia	133.68	45.73	40	2909	1822	1742010
Pseudocholelithiasis	128.99	45.73	18	2931	0	1743832
Immune reconstitution inflammatory syndrome	127.51	45.73	37	2912	1512	1742320
Cholestasis	125.70	45.73	45	2904	3620	1740212
Flank pain	119.68	45.73	32	2917	963	1742869
Drug hypersensitivity	116.24	45.73	65	2884	15070	1728762
Thrombocytopenia	110.53	45.73	71	2878	21178	1722654
Diarrhoea	109.73	45.73	103	2846	53749	1690083
Factor V inhibition	106.45	45.73	18	2931	45	1743787
Haemolysis	105.84	45.73	30	2919	1125	1742707
Hepatocellular injury	104.50	45.73	38	2911	3193	1740639
Vomiting	101.26	45.73	85	2864	38230	1705602
Condition aggravated	101.00	45.73	67	2882	21083	1722749
Crying	94.33	45.73	29	2920	1446	1742386
Stevens-Johnson syndrome	88.53	45.73	34	2915	3323	1740509
Hypersensitivity	85.98	45.73	47	2902	10397	1733435
Angioedema	83.75	45.73	45	2904	9619	1734213
Drug resistance	82.63	45.73	32	2917	3198	1740634
Hepatitis	82.19	45.73	36	2913	4919	1738913
Respiratory failure	81.63	45.73	51	2898	14454	1729378
Clostridium difficile infection	80.91	45.73	27	2922	1754	1742078
Eosinophilia	79.90	45.73	32	2917	3495	1740337
Agranulocytosis	76.03	45.73	31	2918	3545	1740287
Cardiac arrest	74.83	45.73	50	2899	15880	1727952
Multiple organ dysfunction syndrome	74.42	45.73	41	2908	9201	1734631
Disseminated intravascular coagulation	72.31	45.73	30	2919	3584	1740248
Pancreatitis acute	72.03	45.73	31	2918	4056	1739776
Alanine aminotransferase increased	71.16	45.73	44	2905	12234	1731598
Blood urea increased	70.97	45.73	32	2917	4679	1739153
Tachycardia	70.02	45.73	44	2905	12584	1731248
Septic shock	68.11	45.73	37	2912	8072	1735760
Clostridium difficile colitis	67.66	45.73	23	2926	1581	1742251
Pathogen resistance	63.68	45.73	20	2929	1069	1742763
Abdominal pain	63.55	45.73	51	2898	21439	1722393
Oxygen saturation decreased	62.30	45.73	31	2918	5644	1738188
Oral candidiasis	60.07	45.73	20	2929	1289	1742543
Altered state of consciousness	59.89	45.73	26	2923	3471	1740361
Choreoathetosis	59.54	45.73	13	2936	160	1743672
Sphincter of Oddi dysfunction	59.13	45.73	10	2939	25	1743807
Blood creatinine increased	58.87	45.73	41	2908	13905	1729927
Blood alkaline phosphatase increased	58.87	45.73	29	2920	5166	1738666
Unresponsive to stimuli	55.93	45.73	27	2922	4602	1739230
Treatment failure	54.17	45.73	26	2923	4375	1739457
Renal impairment	53.84	45.73	37	2912	12277	1731555
Aspartate aminotransferase increased	53.46	45.73	35	2914	10721	1733111
Drug interaction	51.94	45.73	51	2898	27907	1715925
Erythema multiforme	50.75	45.73	19	2930	1727	1742105
Pseudomembranous colitis	49.82	45.73	14	2935	507	1743325
Renal failure	49.78	45.73	43	2906	19974	1723858
Nocardiosis	49.46	45.73	14	2935	521	1743311
Liver injury	49.37	45.73	19	2930	1863	1741969
Pancytopenia	47.00	45.73	33	2916	11324	1732508
Jaundice	46.31	45.73	26	2923	6036	1737796

Pharmacologic Action:

Source	Code	Description
ATC	J01DD04	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01DD54	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01DD63	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drug
CHEBI has role	CHEBI:88188	drug allergen
FDA EPC	N0000175488	Cephalosporin Antibacterial
FDA CS	M0003827	Cephalosporins

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Gonococcal meningitis	indication	151004
Streptococcal meningitis	indication	4510004	DOID:11574
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Staphylococcal meningitis	indication	12166008
Gonorrhea	indication	15628003	DOID:7551
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Staphylococcal pneumonia	indication	22754005
Streptococcal septicemia	indication	29577008
Acute gonococcal urethritis	indication	29864006
Pneumonia due to Streptococcus	indication	34020007
Gonorrhea of rectum	indication	42746002
Gonococcal infection of joint	indication	44743006
Bacterial arthritis	indication	48245008
Salmonella septicemia	indication	49786009
Lower respiratory tract infection	indication	50417007
Pneumococcal meningitis	indication	51169003
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Gonococcal endocarditis	indication	61048000
Acute gonococcal endometritis	indication	65295003	DOID:7527
Haemophilus influenzae pneumonia	indication	70036007
Infection due to Escherichia coli	indication	71057007
Bacterial infection due to Serratia	indication	71120004
Rhinoscleroma	indication	72409005	DOID:11336
Gonorrhea of pharynx	indication	74372003
Endometritis	indication	78623009	DOID:1002
Bacterial meningitis	indication	95883001	DOID:9470
Infection of bone	indication	111253001
Staphylococcal septicemia	indication	111821004
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Infection due to Enterobacteriaceae	indication	128945009
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Meningococcal meningitis	indication	192644005
Escherichia coli meningitis	indication	192655005
Proteus pneumonia	indication	195888009
Chancroid	indication	266143009	DOID:13778
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infective otitis media	indication	312218008
Infectious disorder of joint	indication	363162000
Meningitis due to Klebsiella mobilis	indication	420585007
Peptostreptococcus infection	indication	135341000119101
Klebsiella Pneumoniae Osteomyelitis	indication
Inflammatory Disease of Female Pelvic Organs	indication
Proteus Mirabilis Osteomyelitis	indication
Peptostreptococcus Peritonitis	indication
Enterobacter Pneumonia	indication
Proteus Joint Infection	indication
Haemophilus Septic Arthritis	indication
Skin and Skin Structure Serratia Infection	indication
E. Coli Peritonitis	indication
Prevention of Perioperative Infection	indication
Haemophilus Influenzae Type B Infections	indication
Adult Gonococcal Conjunctivitis	indication
E. Coli Septic Arthritis	indication
Haemophilus Septicemia	indication
Disseminated Gonococcal Infection	indication
Klebsiella Pneumoniae Peritonitis	indication
H. Influenzae Meningitis	indication
Prevention of Meningococcal Meningitis	indication
Gram-Negative Aerobic Bacillary Pneumonia	indication
Skin and Skin Structure Proteus Infection	indication
Haemophilus Osteomyelitis	indication
Haemophilus Parainfluenzae Pneumonia	indication
Enterobacter Osteomyelitis	indication
Streptococcal Joint Infection	indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea	indication
Klebsiella Joint Infection	indication
EnterobacterJoint Infection	indication
Skin and Skin Structure Morganella Morganii Infection	indication
Streptococcus Osteomyelitis	indication
E. Coli Joint Infection	indication
E. Coli Osteomyelitis	indication
Pyrexia of unknown origin	off-label use	7520000
Lyme disease	off-label use	23502006	DOID:11729
Lyme arthritis	off-label use	33937009
Pseudotuberculosis	off-label use	36753006
Lyme carditis	off-label use	77863005
Infection by Yersinia enterocolitica	off-label use	80960004
Ventilator-acquired pneumonia	off-label use	429271009
Lyme Disease of the Central Nervous System	off-label use
Sexual Transmitted Disease Exposure from Sexual Assault	off-label use
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Acute nephropathy	contraindication	58574008
Hemolytic anemia	contraindication	61261009	DOID:583
Disease of liver	contraindication	235856003	DOID:409
Neonatal hyperbilirubinemia	contraindication	281610001
Pseudomembranous enterocolitis	contraindication	397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.65	acidic
pKa2	4.17	acidic
pKa3	13.31	acidic
pKa4	3.29	Basic
pKa5	0.93	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D-amino-acid oxidase	Enzyme	P14920	OXDA_HUMAN		IC50	5	CHEMBL
Penicillin-binding protein 2	Enzyme		PBP2_ECOLI	INHIBITOR	IC50	6.21	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1B	Enzyme		PBPB_ECOLI	INHIBITOR	IC50	5.74	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1A	Enzyme		PBPA_ECOLI	INHIBITOR	IC50	6.51	WOMBAT-PK	CHEMBL
Peptidoglycan synthase FtsI	Enzyme		FTSI_ECOLI	INHIBITOR	IC50	6.14	WOMBAT-PK	CHEMBL

External reference:

ID	Source
D002443	MESH_DESCRIPTOR_UI
4019667	VUID
N0000147759	NUI
C0007561	UMLSCUI
D00924	KEGG_DRUG
023Z5BR09K	UNII
104376-79-6	SECONDARY_CAS_RN
4923	INN_ID
19841008	SNOMEDCT_US
4019667	VANDF
004849	NDDF
2193	RXNORM
d00052	MMSL
372670001	SNOMEDCT_US
CHEMBL161	ChEMBL_ID
9F2	PDB_CHEM_ID
DB01212	DRUGBANK_ID
CHEBI:29007	CHEBI
5326	IUPHAR_LIGAND_ID
CHEMBL1200995	ChEMBL_ID
CHEMBL3183968	ChEMBL_ID
5479530	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9678	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	14 sections
Ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9768	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	14 sections
Ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9856	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	14 sections
Ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9857	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	14 sections
Ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9858	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	14 sections
Ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9859	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAMUSCULAR	ANDA	14 sections
CEFTRIAXONE AND DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3153	INJECTION, SOLUTION	1 g	INTRAVENOUS	NDA	17 sections
CEFTRIAXONE AND DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3155	INJECTION, SOLUTION	2 g	INTRAVENOUS	NDA	17 sections
Ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	0338-5002	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	14 sections
Ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	0338-5003	INJECTION, SOLUTION	2 g	INTRAVENOUS	ANDA	14 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7332	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7333	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7334	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7335	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7336	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7337	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAMUSCULAR	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7338	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3206	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAMUSCULAR	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3207	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3208	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3209	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3210	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	21695-202	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	15 sections
Ceftriaxone Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	21695-352	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	15 sections
ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	25021-105	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	15 sections
ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	25021-106	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	15 sections
ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	25021-107	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	15 sections
Ceftriaxone	HUMAN PRESCRIPTION DRUG LABEL	1	25021-108	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	15 sections
CEFTRIAXONE	HUMAN PRESCRIPTION DRUG LABEL	1	42254-152	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	15 sections
CEFTRIAXONE	HUMAN PRESCRIPTION DRUG LABEL	1	42254-191	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAMUSCULAR	ANDA	15 sections